Omeros Corporation Files Universal Shelf Registration Statement to Replace Expiring Universal Shelf Registration Statement

  Omeros Corporation Files Universal Shelf Registration Statement to Replace
               Expiring Universal Shelf Registration Statement

PR Newswire

SEATTLE, Oct. 17, 2013

SEATTLE, Oct. 17, 2013 /PRNewswire/ --Omeros Corporation (NASDAQ: OMER) today
announced that it has filed a replacement universal shelf registration
statement (the "2013 Registration Statement") with the Securities and Exchange
Commission (the "SEC"). The 2013 Registration Statement was filed as routine
course of business due to the impending expiration of the company's existing
universal shelf registration statement (the "2010 Registration Statement")
that, under SEC rules, would have expired on Friday, October 18, 2013.
Pursuant to SEC rules, the expiration date of the 2010 Registration Statement
has been extended until the earlier of the effective date of the 2013
Registration Statement or April 16, 2014. Upon effectiveness, the company may
use the 2013 Registration Statement to offer and sell common and preferred
stock, debt securities and other securities having an aggregate offering
amount of no more than $100 million, which is the amount that was registered
under the 2010 Registration Statement. The 2013 Registration Statement, once
it becomes effective, will continue to provide the company with flexibility to
access the public capital markets in response to financing and business
opportunities that may arise from time to time over its expected three-year
term. No sales will occur under the 2013 Registration Statement prior to the
time it becomes effective.

This press release is neither an offer to sell nor the solicitation of an
offer to buy any securities and shall not constitute an offer or solicitation
in any jurisdiction where such offer or solicitation is unlawful.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering,
developing and commercializing small-molecule and protein therapeutics
targeting inflammation, coagulopathies and disorders of the central nervous
system.

Contact:
Jennifer Cook Williams
Cook Williams Communications, Inc.
Investor and Media Relations
360.668.3701
jennifer@cwcomm.org

SOURCE Omeros Corporation
 
Press spacebar to pause and continue. Press esc to stop.